Literature DB >> 28705707

GATA3 as a valuable marker to distinguish clear cell papillary renal cell carcinomas from morphologic mimics.

Jose G Mantilla1, Tatjana Antic2, Maria Tretiakova3.   

Abstract

Clear cell papillary renal cell carcinoma (CCPRCC) is a low-grade, indolent neoplasm with no reported cases of death from disease or metastasis. These lesions can show clinical, morphologic, and immunophenotypic overlap with several aggressive forms of renal cell carcinoma (RCC), including clear cell RCC, translocation RCC, and papillary RCC with cytoplasmic clearing. Given the difference in behavior, it is important to reliably separate these entities. We retrospectively reviewed 47 tumors from 45 patients with morphologic features of CCPRCC. All cases were stained against cytokeratin 7 (CK7), carbonic anhydrase IX (CAIX), and GATA3. Cases inconsistent with CCPRCC were reclassified. In addition, we stained tissue microarrays with 103 typical clear cell RCCs and 62 papillary RCCs, each in triplicate. Twenty-five cases were morphologically and immunophenotypically consistent with CCPRCC; all of them showed diffuse CK7 expression and cup-like reactivity with CAIX. Of these, 19 (76%) showed strong nuclear reactivity for GATA3. Although some non-CCPRCC neoplasms showed at least partial CK7/CAIX coexpression, none were immunopositive for GATA3. All background normal kidneys studied showed GATA3 expression in the distal tubules, collecting ducts, and retention cysts of the distal nephron. On follow-up, none of the patients with CCPRCC had recurrences or metastasis. Sensitivity and specificity for GATA3 staining in the diagnosis of CCPRCC were 76% and 100%, with positive and negative predictive values of 100% and 74%. In conclusion, GATA3 is specific and sensitive for CCPRCC and can be used for accurate distinction from its main mimickers. Coexpression of GATA3 and CK7 in most CCPRCC provides evidence of their origin from distal nephron.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clear cell papillary renal cell carcinoma; GATA3; Genitourinary pathology; Immunohistochemistry; Renal cell carcinoma; Renal neoplasms; Tissue microarray

Mesh:

Substances:

Year:  2017        PMID: 28705707     DOI: 10.1016/j.humpath.2017.06.016

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

Review 1.  Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities.

Authors:  Deepika Sirohi; Steven C Smith; Neeraj Agarwal; Benjamin L Maughan
Journal:  Res Rep Urol       Date:  2018-11-15

2.  Local recurrence of sinonasal renal cell-like adenocarcinoma: A CARE compliant case report.

Authors:  Jian Wu; Qin Fang; Yu-Jie He; Wei-Xiang Chen; Yu-Kai Qi; Jun Ding
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

3.  Urinary nephrospheres indicate recovery from acute kidney injury in renal allograft recipients - a pilot study.

Authors:  Daniela Knafl; Wolfgang Winnicki; Peter Mazal; Ludwig Wagner
Journal:  BMC Nephrol       Date:  2019-07-09       Impact factor: 2.388

4.  Papillary renal neoplasm with reverse polarity: A clinicopathological and molecular genetic characterization of 16 cases with expanding the morphologic spectrum and further support for a novel entity.

Authors:  Miaomiao Shen; Xiaona Yin; Yanfeng Bai; Huizhi Zhang; Guoqing Ru; Xianglei He; Xiaodong Teng; Guorong Chen; Ming Zhao
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

5.  A Simple Bioreactor-Based Method to Generate Kidney Organoids from Pluripotent Stem Cells.

Authors:  Aneta Przepiorski; Veronika Sander; Tracy Tran; Jennifer A Hollywood; Brie Sorrenson; Jen-Hsing Shih; Ernst J Wolvetang; Andrew P McMahon; Teresa M Holm; Alan J Davidson
Journal:  Stem Cell Reports       Date:  2018-07-19       Impact factor: 7.765

Review 6.  Renal Cell Carcinoma in End-Stage Renal Disease: A Review and Update.

Authors:  Ziad M El-Zaatari; Luan D Truong
Journal:  Biomedicines       Date:  2022-03-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.